How should a pregnant woman with suppressed TSH (<0.10 mIU/L), normal free thyroxine (FT4), and elevated free triiodothyronine (FT3) be evaluated and managed?

Management of Pregnant Woman with Suppressed TSH, Normal FT4, and Elevated FT3

This presentation most likely represents either gestational transient thyrotoxicosis (gestational hyperthyroidism) or T3-predominant Graves' disease, and the critical first step is to measure thyroid receptor antibodies (TRAb) to distinguish between these conditions, as this fundamentally determines whether antithyroid drug treatment is needed.

Initial Diagnostic Approach

The biochemical pattern of suppressed TSH (<0.10 mIU/L), normal FT4, but elevated FT3 requires immediate differentiation between two main entities:

Measure TRAb Immediately

• If TRAb is negative or low: This suggests gestational transient thyrotoxicosis, which typically does not require antithyroid drugs 1
• If TRAb is positive (especially >3x upper normal limit): This indicates Graves' disease requiring antithyroid treatment 1

Additional Clinical Context to Assess

• Presence of hyperemesis gravidarum (>5% weight loss, dehydration, ketonuria) 1
• Severity of thyrotoxic symptoms (excessive sweating, weight loss, tachycardia)
• Gestational age and trimester
• History of prior thyroid disease

Management Based on Diagnosis

If Gestational Transient Thyrotoxicosis (TRAb Negative)

Most women with gestational hyperthyroidism, suppressed TSH, and elevated free T4 do not require antithyroid drug treatment 1. However, your patient has elevated FT3 specifically, which creates a clinical dilemma:

• Clinical judgment is essential when total T3 values are above the pregnancy reference range 1
• Consider beta-blockers (metoprolol) for symptomatic relief if significantly thyrotoxic 1
• This condition typically resolves by mid-pregnancy without treatment
• Monitor thyroid function every 2-4 weeks initially

If T3-Predominant Graves' Disease (TRAb Positive)

This is a challenging scenario requiring antithyroid drug therapy with modified monitoring targets:

Treatment Strategy

Initiate propylthiouracil (PTU) in the first trimester 2:

• Starting dose: 50-150 mg daily
• PTU is preferred in first trimester due to lower teratogenic risk compared to methimazole
• Switch to methimazole after first trimester to avoid PTU-associated hepatotoxicity risk 1, 2

Critical Monitoring Targets for T3-Predominant Disease

This is where standard guidelines require adaptation. The conventional approach of targeting FT4 at or just above the upper limit of normal is problematic in T3-predominant disease because:

• Keeping FT4 at upper normal would result in severely elevated FT3 and maternal thyrotoxicosis 3
• The fetus depends primarily on maternal FT4 (not FT3) for development, especially in first trimester
• However, recent case series demonstrate aiming for FT3 at or slightly above the upper limit of normal appears reasonable and safe 3

Recommended monitoring approach 3, 4, 5:

• Target FT3 at or slightly above upper limit of normal to control maternal symptoms
• Accept that FT4 may be low-normal or occasionally low
• Monitor every 2 weeks initially, then every 2-4 weeks 2
• Use both TSH and free T4/T3 for monitoring (TSH may remain suppressed throughout pregnancy) 2

Critical Pitfall: Fetal Goiter Risk

T3-predominant Graves' disease carries higher risk of fetal complications 4, 5:

• Higher TRAb levels are associated with T3-predominance
• Both overtreatment (causing fetal hypothyroidism) and undertreatment (causing fetal hyperthyroidism) can occur
• Monitor for fetal goiter via ultrasound, especially if:
  • Antithyroid drug doses cannot be reduced
  • Maternal thyroid function remains unstable
  • Signs of hydramnios or fetal tachycardia develop

If fetal goiter develops, reduce antithyroid drug dose even if maternal thyroid function is not fully controlled 4

Monitoring Schedule

• Every 2 weeks after treatment initiation or dose changes
• Every 2-4 weeks once stable 2
• Measure FT4, FT3, and TSH (though TSH may remain suppressed)
• Consider fetal ultrasound for thyroid assessment if high TRAb levels or unstable maternal control

When to Consider Treatment Cessation

If on minimal antithyroid drug dose with:

• Satisfactory clinical status
• Normalized maternal FT4 (or FT3 in T3-predominant cases) decreasing on 2 successive assays
• Treatment termination may be considered 2

Key Caveats

• The elevated FT3 with normal FT4 pattern is uncommon and requires careful distinction from gestational transient thyrotoxicosis
• Standard guidelines focus on FT4 targets, but emerging evidence supports FT3-based monitoring in T3-predominant disease 3
• Close collaboration with maternal-fetal medicine is essential given the complexity
• Neonatal thyroid function must be assessed at birth given transplacental passage of TRAb